Genentech Reports Positive Interim Phase 3 Sefaxersen Data
SOUTH SAN FRANCISCO, Calif. — September 22, 2026 Genentech reported positive prespecified interim results from the ongoing Phase 3...
Antisense Oligonucleotide
Advertisement
Roche Reports Positive Phase 3 Sefaxersen Data in IgAN
BASEL, Switzerland — September 23, 2026 Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study...
CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1
WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...
Dyne Therapeutics Advances Z-Basivarsen Toward Phase 3 in DM1
WALTHAM, Massachusetts — September 8, 2026 Dyne Therapeutics announced plans to present additional one-year clinical data from the Phase...
Aptar Pharma, Aceso Advance Inhaled ASO Therapy
Crystal Lake, Illinois — September 7, 2026 Aptar Pharma announced a collaboration with Aceso Therapeutics to advance development activities...
Advertisements
Novartis and Ionis Pharmaceuticals Face Setback in Pelacarsen Trial
Carlsbad, California — September 4, 2026 Ionis Pharmaceuticals and partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON...
Biogen Reports Long-Term Zorevunersen Data in Dravet Syndrome
Bedford, Massachusetts and Cambridge, Massachusetts, USA, September 3, 2026 Biogen Inc. and Stoke Therapeutics have presented new long-term clinical...
Stoke Therapeutics and Biogen Report 4-Year Data Supporting Zorevunersen’s Potential in Dravet Syndrome
Bedford, Massachusetts, USA September 3, 2026 Stoke Therapeutics and Biogen have presented new long-term clinical data supporting the potential...
Stoke Therapeutics and Biogen Present Zorevunersen Data at EEC
ATHENS, Greece, September 1, 2026 Stoke Therapeutics and Biogen announced presentations of clinical data supporting the potential of zorevunersen,...
GSK Wins Japan Approval for Hibsago in Hepatitis B
LONDON, UK, Aug 24, 2026 GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
Advertisement
